Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
30 hedge funds and large institutions have $7.42M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 7 increasing their positions, 5 reducing their positions, and 7 closing their positions.
40% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 5
3% less funds holding
Funds holding: 31 → 30 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
27% less capital invested
Capital invested by funds: $10.2M → $7.42M (-$2.81M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.31M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$1.12M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$253K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$140K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$107K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$3.65M |
| 2 |
FM
Fondren Management
Houston,
Texas
|
-$1.32M |
| 3 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
-$124K |
| 4 |
PCM
Perritt Capital Management
Chicago,
Illinois
|
-$83K |
| 5 |
ASN
Advisory Services Network
Atlanta,
Georgia
|
-$38K |
OPNT Hedge Fund Activity: Q2 2020 in Review
30 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q2 2020, worth a combined $7.42M — down 27% from $10.2M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of OPNT and 6 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.31M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $3.65M sold.
- 30 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q2 2020, down from 31 in Q1 2020.
- Funds reported $7.42M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q2 2020, down 27% quarter-over-quarter.
- 6 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q2 2020 and 7 closed out, a net change of -1 holder.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q2 2020 was Renaissance Technologies, an estimated $1.31M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q2 2020 was Stonepine Capital Management, an estimated $3.65M sold.
Based on aggregated 13F filings for Q2 2020.